Organized around divested neurodegenerative disease candidates from TorreyPines Therapeutics, Annovis Bio Inc (QR Pharma, Inc.) is a specialty pharmaceutical company founded to develop novel drugs for the treatment of Alzheimers Disease (AD), Parkinsons disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development, Posiphen® and Bisnorcymserine (BNC). Both inhibit amyloid formation and may prevent the progression of the disease. However, Posiphen® is better suited for mild cognitive impairment (MCI) and early stage AD and PD and may stop or slow their progression. BNC targets late stage AD and may stabilize the decline.
